Immuneering (IMRX) Total Liabilities (2020 - 2024)
Historic Total Liabilities for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $10.8 million.
- Immuneering's Total Liabilities rose 986.47% to $10.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.8 million, marking a year-over-year increase of 986.47%. This contributed to the annual value of $12.0 million for FY2023, which is 406.38% down from last year.
- Latest data reveals that Immuneering reported Total Liabilities of $10.8 million as of Q3 2024, which was up 986.47% from $10.8 million recorded in Q2 2024.
- Immuneering's Total Liabilities' 5-year high stood at $12.5 million during Q4 2022, with a 5-year trough of $2.8 million in Q4 2020.
- Over the past 5 years, Immuneering's median Total Liabilities value was $9.9 million (recorded in 2023), while the average stood at $9.2 million.
- As far as peak fluctuations go, Immuneering's Total Liabilities skyrocketed by 28294.13% in 2021, and later tumbled by 1640.15% in 2023.
- Quarter analysis of 5 years shows Immuneering's Total Liabilities stood at $2.8 million in 2020, then skyrocketed by 282.94% to $10.7 million in 2021, then rose by 16.71% to $12.5 million in 2022, then fell by 4.06% to $12.0 million in 2023, then dropped by 9.76% to $10.8 million in 2024.
- Its Total Liabilities was $10.8 million in Q3 2024, compared to $10.8 million in Q2 2024 and $9.3 million in Q1 2024.